Galectin Therapeutics
GALT
84 hedge funds and large institutions have $43.9M invested in Galectin Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 16 closing their positions.
98% more capital invested
Capital invested by funds: $22.2M → $43.9M (+$21.7M)
76% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $728K
0.51% less ownership
Funds ownership: 16.61% → 16.1% (-0.51%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 86 → 84 (-2)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.97M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$953K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$328K |
| 4 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
+$313K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.76M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$513K |
| 3 |
BlackRock
New York
|
-$354K |
| 4 |
SIA
Soltis Investment Advisors
St. George,
Utah
|
-$297K |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$237K |
GALT Hedge Fund Activity: Q3 2025 in Review
84 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2025, worth a combined $43.9M — up 98% from $22.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GALT and 15 opened new positions — a net loss of 1 holder — while 26 trimmed existing stakes and 21 added.
The largest buyer was Marshall Wace, adding an estimated $1.97M. The largest seller was Jane Street, cutting an estimated $2.76M.
- 84 institutional investors held Galectin Therapeutics (GALT) as of Q3 2025, down from 86 in Q2 2025.
- Funds reported $43.9M of Galectin Therapeutics stock for Q3 2025, up 98% quarter-over-quarter.
- 15 funds opened new Galectin Therapeutics positions in Q3 2025 and 16 closed out, a net change of -1 holder.
- The largest Galectin Therapeutics buyer in Q3 2025 was Marshall Wace, an estimated $1.97M added.
- The largest Galectin Therapeutics seller in Q3 2025 was Jane Street, an estimated $2.76M sold.
Based on aggregated 13F filings for Q3 2025.